VANGUARD GROUP INC 13D and 13G filings for Crinetics Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-26 5:40 pm Sale | 2026-03-13 | 13G | CRINETICS PHARMACEUTICALS INC CRNX | VANGUARD GROUP INC | 0 0.000% | -9,311,600 (Position Closed) | Filing |
| 2025-04-07 11:52 am Purchase | 2025-03-31 | 13G | CRINETICS PHARMACEUTICALS INC CRNX | VANGUARD GROUP INC | 9,311,600 10.000% | 222,209 (+2.44%) | Filing |
| 2025-01-30 9:33 pm Purchase | 2024-12-31 | 13G | CRINETICS PHARMACEUTICALS INC CRNX | VANGUARD GROUP INC | 9,089,391 9.800% | 2,801,736 (+44.56%) | Filing |
| 2024-11-12 2:26 pm Unchanged | 2024-09-30 | 13G | CRINETICS PHARMACEUTICALS INC CRNX | VANGUARD GROUP INC | 6,287,655 7.850% | 0 (Unchanged) | Filing |
| 2024-11-04 11:20 am Purchase | 2024-09-30 | 13G | CRINETICS PHARMACEUTICALS INC CRNX | VANGUARD GROUP INC | 6,287,655 7.850% | 2,785,203 (+79.52%) | Filing |
| 2024-02-13 5:02 pm Purchase | 2023-12-29 | 13G | CRINETICS PHARMACEUTICALS INC CRNX | VANGUARD GROUP INC | 3,502,452 5.240% | 3,502,452 (New Position) | Filing |